Dennis Purcell‘s Aisling Capital has sold off nearly 1.00 million shares of Cempra Inc (NASDAQ:CEMP) since the end of December according to a new 13D filing. Cempra has been one of Mr. Purcell’s top holdings since the middle of 2014 and the position has been a rewarding one for the investor, with shares having advanced by about 48% since then. Nonetheless, they are well off their highs from July 2015, when they topped $45 briefly, having fallen by 62% since then. Mr. Purcell did sell about one-third of his holding in the second quarter of 2015, when shares were over 100% higher than they are today. Aisling Capital now holds 1.23 million shares of Cempra.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Aisling Capital II | 1,232,278 | 0 | 1,232,278 | 0 | 1,232,278 | 2.6% |
| Aisling Capital Partners | 1,232,278 | 0 | 1,232,278 | 0 | 1,232,278 | 2.6% |
| Aisling Capital Partners | 1,232,278 | 0 | 1,232,278 | 0 | 1,232,278 | 2.6% |
| Steve Elms | 3,819 | 1,232,278 | 3,819 | 1,232,278 | 1,236,097 | 2.6% |
| Dennis Purcell | 7,390 | 1,232,278 | 7,390 | 1,232,278 | 1,239,668 | 2.6% |
| Andrew Schiff | 382 | 1,232,278 | 382 | 1,232,278 | 1,232,660 | 2.6% |
Page 1 of 9 SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2)*
Cempra, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
15130J 109
(CUSIP Number)
Lloyd Appel
Aisling Capital
888 Seventh Avenue, 12th Floor
New York, NY 10106
(212) 651-6380
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 7, 2016
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
Follow Melinta Therapeutics Inc. W (NASDAQ:MLNT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9
